因素 | GSU组(50) | 非GSU组(120) | t/c2/Z | p值 |
年龄(岁) | 68.34 ± 6.20 | 68.55 ± 6.91 | 0.186 | 0.853 |
根治活检时间间隔(天) | 36.00 (12.00~48.75) | 30.50 (12.00~49.00) | 0.368 | 0.713 |
BMI (kg/m2) | 26.17 ± 2.86 | 25.60 ± 3.36 | −1.041 | 0.299 |
单核细胞(×109/L) | 0.54 ± 0.18 | 0.48 ± 0.14 | −2.203 | 0.029 |
淋巴细胞(×109/L) | 1.84 ± 0.54 | 1.74 ± 0.59 | −0.997 | 0.320 |
中性粒细胞(×109/L) | 4.11 ± 1.37 | 3.66 ± 1.18 | −2.152 | 0.033 |
NLR | 2.00 (1.74~3.01) | 1.91 (1.46~2.97) | −0.855 | 0.393 |
tPSA (ng/ml) | 19.55 (11.93~27.58) | 15.02 (8.81~31.54) | −1.247 | 0.213 |
fPSA (ng/ml) | 2.12 (1.47~3.87) | 2.24 (1.15~3.44) | −0.624 | 0.533 |
f/tPSA (%) | 0.12 (0.09~0.14) | 0.12 (0.09~0.19) | −1.293 | 0.196 |
PV (ml) | 39.38 (28.78~60.17) | 42.86 (28.60~61.59) | −0.465 | 0.642 |
评分最高针肿瘤组织占比(%) | 45.00 (30.00~72.00) | 60.00 (20.00~80.00) | −0.321 | 0.748 |
活检阳性针数(针) | 3.00 (2.00~8.00) | 5.00 (2.00~9.00) | −1.496 | 0.135 |
PSAD | 0.46 (0.25~0.86) | 0.37 (0.19~0.86) | −1.170 | 0.242 |
民族 |
|
|
|
|
汉族 | 27 (29.34) | 65 (70.65) | 0.637 | 0.727 |
维族 | 16 (32.65) | 33 (67.35) |
|
|
其他 | 7 (24.14) | 22 (75.86) |
|
|
活检Gleason分组 |
|
|
|
|
1 | 22 (38.60) | 35 (61.40) | 23.24 | 0.000 |
2 | 15 (45.45) | 18 (54.54) |
|
|
3 | 10 (38.46) | 16 (61.54) |
|
|
4 | 3 (12.50) | 21 (87.50) |
|
|
5 | 0 | 30 |
|
|
高血压史 |
|
|
|
|
有 | 18 (27.27) | 48 (72.72) | 0.238 | 0.626 |
无 | 32 (30.77) | 72 (69.23) |
|
|
糖尿病史 |
|
|
|
|
有 | 10 (35.71) | 18 (64.29) | 0.641 | 0.423 |
无 | 40 (28.17) | 102 (71.83) |
|
|
内分泌治疗史 |
|
|
|
|
有 | 17 (30.90) | 38 (69.09) | 0.088 | 0.767 |
无 | 33 | 82 |
|
|